• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Transfusion . Risk of transfusion-transmitted infection with severe acute respiratory syndrome coronavirus 2 from blood donors in Japan

tetano

Editor, Senior Moderator
Transfusion


. 2023 Dec 13.
doi: 10.1111/trf.17622. Online ahead of print. Risk of transfusion-transmitted infection with severe acute respiratory syndrome coronavirus 2 from blood donors in Japan

Naoya Shinohara[SUP] 1 [/SUP], Mai Ito[SUP] 2 [/SUP], Kazuhiro Kai[SUP] 2 [/SUP], Noriyuki Kamo[SUP] 1 [/SUP], Takashi Owada[SUP] 1 [/SUP], Rieko Sobata[SUP] 1 [/SUP], Naoji Yamagishi[SUP] 1 [/SUP], Hideyuki Takahashi[SUP] 1 [/SUP], Yohei Ikeda[SUP] 1 [/SUP], Hiromi Sawai[SUP] 1 [/SUP], Rika A Furuta[SUP] 1 [/SUP], Keiji Matsubayashi[SUP] 1 [/SUP], Ikuo Hino[SUP] 2 [/SUP], Naoko Goto[SUP] 2 [/SUP], Masahiro Satake[SUP] 1 [/SUP]



Affiliations
Abstract

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) essentially affects respiratory organs and tissues. SARS-CoV-2 RNAemia is often associated with more severe cases of coronavirus disease 2019 (COVID-19) compared to cases without RNAemia. To determine the impact of the pandemic on transfusion medicine, particularly transfusion-related infection, we examined the frequency of blood donation with RNAemia, the viral RNA (vRNA) concentration, and any possibility of transfusion-transmitted infection (TTI) among transfusion recipients.
Study design and methods: vRNA was examined in plasma/serum samples from 496 of 513 blood donors who reported having been infected with SARS-CoV-2 within 2 weeks of donation among a total of ca. 9.9 million blood donations in Japan between January 15, 2020, and December 31, 2021. The clinical course of patients transfused with the blood component containing vRNA was also examined.
Results: vRNA was detected in 23 of 496 samples. The median period from blood donation to COVID-19 onset was 1 day in 16 RNAemia-positive donors. Most samples had vRNA concentrations below the limit of quantification. Three patients were transfused with either a packed red blood cell or platelet concentrate that tested positive for vRNA, showing no COVID-19 symptoms and testing negative for vRNA in post-transfusion blood.
Conclusion: The rate of RNAemia was 4.6% among blood donors who were found to be infected with SARS-CoV-2 shortly after donation, and vRNA concentrations in their donated blood were extremely low. There was no evidence of TTI in the recipients transfused with RNAemia-positive blood components. TTI risk in SARS-CoV-2 is negligible.

Keywords: COVID-19; SARS-CoV-2; transfusion.

 
Back
Top Bottom